查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1746599

日本心臟生物标记市场报告（按类型（肌钙蛋白、心肌肌酸激酶、肌红蛋白、脑钠肽或 NT-proBNP、缺血修饰白蛋白等）、检测地点、应用和地区）2025 年至 2033 年

Japan Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 120 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024年，日本心臟生物标记市场规模达6.801亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到13.027亿美元，2025-2033年期间的复合年增长率（CAGR）为7.5%。心臟病发作、中风和心臟衰竭等心血管疾病的发生率不断上升，这些疾病需要利用心臟生物标记进行早期检测、风险评估和患者监测，从而推动市场发展。

心臟生物标记是心臟相关疾病发生时释放到血液中的蛋白质或分子。它们在诊断和监测各种心臟疾病中发挥着至关重要的作用。常见的心臟生物标记包括肌钙蛋白、肌酸激酶同工酶 (CK-MB) 和 B 型利钠肽 (BNP)。肌钙蛋白是心肌损伤的高度特异性指标，在诊断心臟病发作中至关重要。 CK-MB 是另一种因心肌损伤而升高的酵素。而 BNP 则有助于评估心臟衰竭及其严重程度。透过血液检测测量心臟生物标记物，医疗保健专业人员可以检测和评估心臟问题，确定损伤程度，并制定合适的治疗方案。这些生物标记为心臟整体健康状况提供了宝贵的见解，并有助于指导医疗干预措施以改善患者预后。定期监测心臟生物标记对于管理心臟疾病和预防併发症至关重要。

日本心臟生物标记市场趋势：

日本的心臟生物标记市场预计将大幅成长，这主要得益于以下几个关键因素。首先，心血管疾病（包括冠状动脉疾病和心臟衰竭）的盛行率不断上升，显着增加了对心臟生物标记检测的需求。此外，该地区人口老化也是一个主要驱动因素，因为老年人患心臟相关疾病的风险更高，从而对心臟生物标记诊断的需求持续增长。此外，医疗技术的进步和高灵敏度心臟生物标记检测的日益普及，提高了心臟疾病检测的准确性和效率。这不仅改善了患者的预后，也鼓励医疗保健提供者将这些检测纳入其常规临床实践。此外，医疗保健专业人员和患者对早期发现和预防心臟疾病重要性的认识不断提高，也导致了检测率的提高。对预防性医疗保健和主动监测心臟健康的重视，促进了心臟生物标记市场的发展。最后，政府的支持性措施以及对心血管研究和诊断工具的资助，也推动了市场扩张。总体而言，这些驱动因素共同为心臟生物标记市场在可预见的未来持续成长创造了有利的前景。

日本心臟生物标记市场细分：

类型洞察：

  • 肌钙蛋白（T 和 I）
  • 心肌肌酸激酶（CK-MB）
  • 肌红蛋白
  • 脑钠肽 (BNPs) 或 NT-proBNP
  • 缺血修饰白蛋白（IMA）
  • 其他的

测试洞察的位置：

  • 实验室测试
  • 即时检验

应用程式洞察：

  • 心肌梗塞
  • 充血性心臟衰竭
  • 急性冠状动脉综合症
  • 动脉粥状硬化
  • 其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本心臟生物标记市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对日本心臟生物标记市场有何影响？
  • 日本心臟生物标记市场依类型分为哪些类型？
  • 根据检测地点，日本心臟生物标记市场是如何分類的？
  • 根据应用情况，日本心臟生物标记市场是如何分類的？
  • 日本心臟生物标记市场的价值链分为哪些阶段？
  • 日本心臟生物标记的主要驱动因素和挑战是什么？
  • 日本心臟生物标记市场的结构是怎么样的？主要参与者是谁？
  • 日本心臟生物标记市场的竞争程度如何？

本报告回答的关键问题：

  • 日本心臟生物标记市场迄今表现如何？未来几年将如何表现？
  • COVID-19 对日本心臟生物标记市场有何影响？
  • 日本心臟生物标记市场依类型分为哪些类型？
  • 根据检测地点，日本心臟生物标记市场是如何分類的？
  • 根据应用情况，日本心臟生物标记市场是如何分類的？
  • 日本心臟生物标记市场的价值链分为哪些阶段？
  • 日本心臟生物标记的主要驱动因素和挑战是什么？
  • 日本心臟生物标记市场的结构是怎么样的？主要参与者是谁？
  • 日本心臟生物标记市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本心臟生物标记市场 - 简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本心臟生物标记市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本心臟生物标记市场-分类：依类型

  • 肌钙蛋白（T 和 I）
    • 概述
  • 心肌肌酸激酶（CK-MB）
    • 概述
  • 肌红蛋白
    • 概述
  • 脑钠肽 (BNPs) 或 NT-proBNP
    • 概述
  • 缺血修饰白蛋白（IMA）
    • 概述
  • 其他的

第七章：日本心臟生物标记市场-细分：依检测地点

  • 实验室测试
    • 概述
  • 即时检验
    • 概述

第 8 章：日本心臟生物标记市场 - 细分：按应用

  • 心肌梗塞
    • 概述
  • 充血性心臟衰竭
    • 概述
  • 急性冠状动脉综合症
    • 概述
  • 动脉粥状硬化
    • 概述
  • 其他的

第九章：日本心臟生物标记市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第十章：关键参与者简介

  • Company A
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 11 章：日本心臟生物标记市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 12 章：附录

简介目录
Product Code: SR112025A19462

Japan cardiac biomarkers market size reached USD 680.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,302.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.5% during 2025-2033. The increasing prevalence of cardiovascular diseases such as heart attacks, strokes, and heart failure, that require cardiac biomarkers for early detection, risk assessment, and monitoring of patients, is driving the market.

Cardiac biomarkers are proteins or molecules released into the bloodstream in response to heart-related conditions. They play a crucial role in diagnosing and monitoring various heart disorders. Common cardiac biomarkers include troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP). Troponins are highly specific indicators of heart muscle damage and are essential in diagnosing heart attacks. CK-MB is another enzyme that rises in response to heart muscle injury. BNP, on the other hand, helps assess heart failure and its severity. Measuring cardiac biomarkers through blood tests allows healthcare professionals to detect and evaluate heart problems, determine the extent of damage, and formulate appropriate treatment plans. These biomarkers provide valuable insights into the overall health of the heart and help guide medical interventions to improve patient outcomes. Regular monitoring of cardiac biomarkers is essential in managing heart conditions and preventing complications.

Japan Cardiac Biomarkers Market Trends:

The cardiac biomarkers market in Japan is poised for substantial growth, driven by several key factors. Firstly, the escalating prevalence of cardiovascular diseases, including coronary artery disease and heart failure, has significantly increased the demand for cardiac biomarker testing. Additionally, the aging regional population is a major driver, as older individuals are at higher risk of cardiac-related issues, creating a sustained need for cardiac biomarker diagnostics. Moreover, advancements in medical technology and the increasing adoption of high-sensitivity cardiac biomarker assays have enhanced the accuracy and efficiency of cardiac disease detection. This has not only improved patient outcomes but also encouraged healthcare providers to incorporate these tests into their routine clinical practices. Furthermore, the growing awareness among both healthcare professionals and patients regarding the importance of early cardiac disease detection and prevention has led to increased testing rates. The emphasis on preventive healthcare and proactive monitoring of cardiac health has bolstered the cardiac biomarkers market. Lastly, supportive government initiatives and funding for cardiovascular research and diagnostic tools have fueled market expansion. Overall, these drivers converge to create a favorable landscape for the cardiac biomarkers market's sustained growth in the foreseeable future.

Japan Cardiac Biomarkers Market Segmentation:

Type Insights:

  • Troponins (T and I)
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

Location of Testing Insights:

  • Laboratory Testing
  • Point of Care Testing

Application Insights:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cardiac biomarkers market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cardiac biomarkers market?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of type?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of location of testing?
  • What is the breakup of the Japan cardiac biomarkers market on the basis of application?
  • What are the various stages in the value chain of the Japan cardiac biomarkers market?
  • What are the key driving factors and challenges in the Japan cardiac biomarkers?
  • What is the structure of the Japan cardiac biomarkers market and who are the key players?
  • What is the degree of competition in the Japan cardiac biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cardiac Biomarkers Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cardiac Biomarkers Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Cardiac Biomarkers Market - Breakup by Type

  • 6.1 Troponins (T and I)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Myoglobin
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)
  • 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Forecast (2025-2033)
  • 6.5 Ischemia Modified Albumin (IMA)
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2019-2024)
    • 6.5.3 Market Forecast (2025-2033)
  • 6.6 Others
    • 6.6.1 Historical and Current Market Trends (2019-2024)
    • 6.6.2 Market Forecast (2025-2033)

7 Japan Cardiac Biomarkers Market - Breakup by Location of Testing

  • 7.1 Laboratory Testing
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Point of Care Testing
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)

8 Japan Cardiac Biomarkers Market - Breakup by Application

  • 8.1 Myocardial Infarction
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Congestive Heart Failure
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Acute Coronary Syndrome
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)
  • 8.4 Atherosclerosis
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2019-2024)
    • 8.4.3 Market Forecast (2025-2033)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2019-2024)
    • 8.5.2 Market Forecast (2025-2033)

9 Japan Cardiac Biomarkers Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Services Offered
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Services Offered
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Services Offered
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Services Offered
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Services Offered
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Cardiac Biomarkers Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix